MOMO'S BREAKOUT BOARD

[Stock Predictor]

federal restrictions on pot. Weed stocks are over!

[Stock Predictor]

Pot is over.

[i_like_bb_stock]

SAGD news out SAGD Progressing with PotPons

Jan 05, 2018
OTC Disclosure & News Service

Las Vegas, NV -

January 5, 2018. South American Gold Corp (OTC: SAGD), is pleased to announce that great progress is being made with PotPons. SAGD CEO David Reeves would also like to take the opportunity to more fully outline PotPons and its varied applications.



According to Reeves, "To understand the success path of PotPons, one must first understand that PotPons is really two completely separate products, branded under the same name. On the one hand, we have PotPons Coins, the P2P tradeable cryptocurrency which was designed, with full market integration, to be owned by the people with no one single controller. In addition, have PotPons Merchant Services System, which is designed to initially service the Medical Marijuana Industry utilizing the PotPons Coin as the virtual currency which will act as an alternative payment solution to cash."



Reeves continued, "It is our belief that the success of a coin relies directly upon the community that accepts the coin. First, we must move to get the publics belief in the PotPons Coin Mission Statement and their acceptance of that in the market. Second, we must directly and through the community, obtain acceptance by multiple mid-level and high-level trading platforms, including our agreed first platform of BitTraderPro.com, a product of Favored, Inc. (OTC: FVRD). Third, we must keep the name of PotPons in the markets view to grow the recognition while increasing the circulation supply. Fourth, we must strive to add both horizontal and vertical market acceptance of the Coin to increase the desirability of the PotPons Coin. The success of PotPons Coin is solely based upon the cryptocurrency communitys awareness and interest.



Regarding the PotPons Merchant Services System, the US market is a multi-billion dollar market that needs a safer way to process transactions, given that all other competitors in this space are not US based. The PotPons Merchant System is designed to be fully transparent providing the records needed utilizing the State Chartered Banking Systems.



According to Reeves, The PotPons Merchant System is different from previous attempts by the competition in several respects: we are a US company, that understands the present rules and regulations; we are ever-growing in knowledge as the rules and regulations are changed so we can quickly adapt accordingly; and we will offer benefits to the merchants that have not been seen in this industry before from groups trying to provide an alternative to cash since we will have personal interactions with our merchants.



About South American Gold Corp:

South American Gold Corp is a publicly traded company on the OTC under the symbol SAGD, focused on enhancing shareholder value by acquiring and operating undervalued assets.

For more information:

Corporate Website: www.sagdcorp.co

Media contact: [e-mail]

General contact: [e-mail]

Disclaimer: This release contains forward-looking statements that are based on beliefs of South American Gold Corp. management and reflect South American Gold Corp.'s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities and Exchange Act of 1934, as amended. When we use in this release the words "estimate," "project," "looks," "believe," "anticipate," "intend," "expect," "plan," "predict," "may," "should," "will," "can," the negative of these words, or such other variations thereon, or comparable terminology, are all intended to identify forward looking statements. Such statements reflect the current views of South America Gold Corp. with respect to future events based on currently available information and are subject to numerous assumptions, risks and uncertainties, including but not limited to, risks and uncertainties pertaining to development of mining properties, changes in economic conditions and other risks, uncertainties and factors, which may cause the actual results, performance, or achievement expressed or implied by such forward looking statements to differ materially from the forward looking statements. The information contained in this press release is historical in nature, has not been updated, and is current only to the date shown in this press release. This information may no longer be accurate and therefore you should not rely on the information contained in this press release. To the extent permitted by law, South American Gold Corp. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission. This press release may incorporate by reference the Company's reports and other filings. Investors are encouraged to review all filings. There is no assurance South American Gold Corp. will identify projects of merit or if it will have sufficient financing to implement its business plan. There is no assurance that the Company's due diligence on the potential projects and/or acquisitions will be favorable nor that definitive terms can be negotiated. Investors should consult their financial advisor before making an investment in a company.

Copyright © 2018 OTC Markets. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

[INTHEKNOW1]

***MUST SEE FOR OTC TRADERS/INVESTORS***
https://madmimi.com/s/7fa05b?o=tm
FUTURE BILLION DOLLAR COMPANY...OTTV.0017

GLOBAL ADVERTISEMENT CAMPAIGN HAS JUST BEGUN.

4.8 OUT OF 5 STAR RATING FROM CURRENT CUSTOMERS.

FANTASTIC PRODUCT AND EVEN BETTER CUSTOMER SERVICE.
(I KNOW, I SUBSCRIBE)

R&D STAGE IS OVER...........IT's REVENUE TIME

GET 10 TIMES THE VIEWING FOR 1/4 THE COST OF CABLE.

REVENUE POTENTIAL... $35. TIMES 12 MONTHS TIMES GLOBAL CUSTOMERS

EARLY BIRDS GET THE WORMS...

HTTP://vivalivetv.com

[Let's Roll]

$ADAC Closed up 8.14% yesterday! On watch here for an update soon.

[Cheetah Man Iowa]

Ignore Jeff Sessions When It Comes To Terra Tech Corp (OTCMKTS:TRTC)

https://insiderfinancial.com/ignore-jeff-sessions-when-it-comes-to-terra-tech-corp-otcmktstrtc/174748/

[stockseekerok]

CBIS News __ Cannabis Science Has US Federal Government Clearance that Changes the Industry, Access to Federal Government Contracts, Supported US Federal Governments Since 2009, Looks for New Federal Policy to Properly Regulate Industry for Patients

IRVINE, CA, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce its support for the U.S. Federal Government, and the Company intends to step in with its experts to assist the Federal Government. The Company is looking to establish new Federal marijuana policy and calls on Department of Justice (DOJ) to help establish a properly-regulated Federal Policy for all patients’ safe access to pharmaceutical and pharmacy dispensed cannabinoids for various critical ailments.

Cannabis Science has launched several initiatives to study the use of cannabinoid-based medicines. For one such initiative, initial results on using nanoparticle drones to target and successfully kill stage four lung cancer cells with radiosensitizers and cannabinoids have been published in the cancer research journal “Frontiers in Oncology”.

The article can be viewed at https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full

This publication of our work has clearly documented our success in a one of the leading Oncology publications as evidence of our cannabinoid research expertise. “Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids,” addresses drug delivery, and highlights an innovative strategy to deliver cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.

Equally important, Cannabis Science has the grit in the industry: it has been registered and received its initial Federal Commercial and Government Entity (CAGE) Code clearance back in 2009. Cannabis Science is one of the only companies in its industry with the ability to work directly with the US Federal Government. Cannabis Science clearly intends to use its relationships and vast expertise within its team from a number of Government Agencies, University Medical Research, Government Medical Research, Pharmaceutical Drug Development, Pharmacy Dispensing, and a number of other key points on this matter. Cannabis Science will promptly address the divergences with the Federal Government and the American people who are actually looking to treat their ailments using pharmaceutical and pharmacy dispensed cannabinoids across the Country.

“As a research-based company, CBIS’ focus is on pharmaceutical drug development and on creating medicines that can help patients in need,” stated Dr. Allen Herman, CBIS’ Chief Medical Officer. “We believe there are a number of indications that can be effectively treated with cannabinoid-based medicines and we expect our research, development, and clinical trial initiatives to demonstrate this.”

The U.S. Federal Government clearance clearly places Cannabis Science as one of THE Leading Publicly Traded Company in this industry looking to establish a Federal regulatory governing body to convene over the laws, regulations and compliance of the cannabis industry. Cannabis Science, Inc. has also conducted its business in this manner since the 2009 approval from the U.S. Federal Government as if these policies and procedures had been established at a Federal level. Cannabis Science, Inc. wants to work hand in hand with the establishment of federal laws and regulations, work within the federal laws and regulations that already exist and with the federal agencies charged with enforcing them.

Cannabis Science is registered in SAM with three North American Industry Classification System (NAICS) Codes:

541711 – Research and Development in Biotechnology
621511 – Medical Laboratories
624230 – Emergency and Other Relief Services

“Cannabis Science is currently exploring a number of Federal government contracts and grant opportunities, individually and with its collaborators, with institutions such as the National Institutes of Health (NIH), institutes within NIH, such as the National Institute on Drug Abuse (NIDA), and others. There is a certain level of clearance Cannabis Science has received from the Defense Logistics Agency’s CAGE Program Office at the U.S. Department of Defense for the Federal Commercial and Government Entity (CAGE) Code program that allows CBIS instant access to U.S. Federal Government contract procurement and that puts the Company directly in line to benefit from the cannabinoid-based medicines industry,” stated Mr. Dabney. “As for the U.S. Federal Government, we believe we have a significant role to play, as a private sector stakeholder, as well as a company that can support federally-funded contracts and grant opportunities as an experienced contractor. Our Team is honored to be a part of the process involved with the establishment of these Laws, Policies, Regulations and Compliance and possibly become a part of the business model for the private sector to adhere to.”

[1jk1]

$GCEI ALERT> January Effect https://www.investopedia.com/terms/j/januaryeffect.asp

GROSSLY UNDERVALUED


www.globalcleanenergy.net/


Go GREEN with Global Clean Energy a Enviromentally Friendly Waste Tires to Fuel & Algae to Products Company


glta

[slam4202]

ALYI - Alternet Systems Announces Spinoff And Dividend Strategy To Unlock Shareholder Value.
https://www.otc-alyi.com/

[slam4202]

ALYI...MOTORCYCLE/MOPED ELECTRIFICATION IN A MULTI-BILLION ASIAN AND EUROPEAN MARKET.
GLTA
SLAM

[Ronin]

APRU .0018 MJ CBD play, doing business with MJNA!

APRU has 52 week high and holding. A new run is beginning and it will be a MONSTER one since CEO says 2018 will be a "great year!"

Final delivery for the year! More Chews to Kannaway! Its been a great year so stay tuned. #doinitright $APRU $MJNA

— Apple Rush Company (@RealAPRU_NEWS) December 29, 2017

I know you want more, but new revenue stream coming soon. Waiting for a document to finalize fins. 2018 will be great. $APRU #doinitright pic.twitter.com/IhucAVZ1mO

— Apple Rush Company (@RealAPRU_NEWS) December 29, 2017

GET IN!!!!

[Wild Wild West]

TGGI. 0003 was up eod! Unique Patented Cannabis products coming to market, big MJ deals in the works, massive share buy back/reduction coming! Many more great things coming.

[Drugdoctor]

$ICNB.0054- Forget Cryptos and Weed - WINE is FINE!!!!....

And this overlooked STOCK is looking mighty fine coming off a huge sale in 1150 PUBLIX STORES!

[Djdjdjdj]

i told you about LIBE at 0088 now 0280 still way undervalued

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Announces Production of Master Cell Bank PMCB



LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the production of the cells necessary to prepare the Master Cell Bank (MCB) has started. This important work is being carried out by Eurofins, a leading Contract Manufacturing Organization, PharmaCyte selected for this task. Successful development of the MCB is a critical step in PharmaCyte’s preparation for its pancreatic cancer clinical trial.

“The decision to forego a WCB was made because we believe that the MCB will contain more than enough cells for the clinical trial. The goal is to validate PharmaCyte’s unique technology at the earliest opportunity.”
Tweet this
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “The commencement of the Master Cell Bank (MCB) by Eurofins means that many of the problems discussed during the shareholder call on November 1st have been overcome. When the MCB has been fully populated, the cells will undergo a variety of tests to ensure that they are correct in all respects and then placed in frozen storage for encapsulation and further testing by Austrianova.”

In consultation with principals at Austrianova, PharmaCyte has decided that, once the MCB is fully populated and successfully tested, cells from the MCB will be shipped to Austrianova and used for encapsulation. These encapsulated cells will then be used, along with low-doses of the cancer prodrug ifosfamide, in PharmaCyte’s pancreatic cancer clinical trial.

Waggoner added, “PharmaCyte has decided to proceed with only the MCB for the upcoming clinical trial and, as previously discussed, a Working Cell Bank (WCB) is not required. This will save both a significant amount of time and cost for PharmaCyte in the overall development process of the production of the encapsulated cells.

“The decision to forego a WCB was made because we believe that the MCB will contain more than enough cells for the clinical trial. The goal is to validate PharmaCyte’s unique technology at the earliest opportunity.”

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Contacts
Investor Relations:
PharmaCyte Biotech, Inc.
Dr. Gerald W. Crabtree
Investor Relations Department
917.595.2856
[e-mail]

[$Pistol Pete$]

$EQLB Last Shot Science EQLB

Last Shot has some key ingredients; Glucorate can help remove toxins in the liver. This allows for your body to DETOX more efficiently and may help cell damage and dehydration associated with playing hard at night and during the day.

[l2 hunter]

VUME 0135 +12.5% 12 MONTH CHART >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

[stealofadeal]

VSTR This stock is in breakout mode and looking very good. $$$$$

[stockmaster007]

Check out $PAOG$ https://www.pao.group/

[ClayTrader]

I flew to Baltimore to visit a day trading friend of mine who is quite successful. He walked me through his daily routine in detail which you can watch and the free video HERE

[TheGreenReaper]

GYOG Chart
8 day is turning up [purple]
Price is holding above 50 day[white] @ 0.0004 (Which is support)
Close above 200 day @ 0.0007 and we are golden [Yellow]
RSI is cooling down...

[beambe]

ACNNF goo 1000%

[insymbols]

i agree $BRGO

[BottomBounce]

$KNDI 2nd Resistance Point 8.60
1st Resistance Point 7.77
Last Price 7.20

[BottomBounce]

* * $GEVO a Buy @ Barchart * * https://www.barchart.com/stocks/quotes/GEVO

[BottomBounce]

* * $PPPMF Chart 01-04-18 * *

[stockmaster007]

$PAOG - cannabis play legally. Sessions work around.

[Welcome2Pinkyland]

i like easy money $$$

[BottomBounce]

$GEVO easy $1+ for 2018 imo

[BottomBounce]

$GEVO easy $1+ for 2018 imo

[BottomBounce]

$PPPMF accumulation at .07

[BottomBounce]

$KNDI MACD Bullish Cross @ end of day. Nice new up trend

[BottomBounce]

* * $KNDI Chart 01-04-18 * *

[BottomBounce]

* * $GEVO Chart 01-04-18 * *

[ospreyeye]

$CNET $CNIT $CCIH $CCCR $CCCL $IZEA $HTGM $MCEP $DSS $IBIO $BNTC Charts 1/4/17

TA Video

$

[Welcome2Pinkyland]

$EBYH Strains for pains- MMJ 2018 news letter:

https://www.dropbox.com/s/m5t0u56yx82jycs/SFP_newsletter__2018.pdf?dl=0

http://strainsforpains.com/compliance-and-news/

[kex0414]

Re:AFTC: False and misleading information. AFTC was reinstated 4 years ago 2014 for the sole purpose of dissolving the company.Revoked in 2015

The Company never owned a patent. Not one. Not now; not ever.

Alternative Fuel Technologies DME patents from 1976 to present

Alternative Fuel Technologies JP-8 patents from 1976 to present

Alternative Fuel Technology DME and/or JP-8 patents from 1976 to present

[Warchest]

$MRJT $MRJT $MRJT $MRJT

[Golden Cross]

$SIPC Retrace and Bounce off 50dma Very Strong!

#SIPC GLTA

[ClayTrader]

The next time someone accuses me of shorting, or being a "curse"... just understand, they're a BASHER. My proof = CLICK HERE

[9754LB851]

pharmaceutical NPHC pain meds and upcoming clinical trials for pediatric MS medicine. 10 drug pipeline including HIV/MS/Herpies meds. 21 patents. Orphan drug status. CEO stated no R/S at this time. Unrestricted 1.8+ b - a.s 2b. Expecting significant funding and phase II news in the future

[Golden Cross]

$VATE Elev8 HEMP Tea's Now Sold On eBay!

https://www.ebay.com/usr/elev8hemp?_trksid=p2047675.l2559

#VATE

[DewmBoom]

$BIEL is my No. 1 stock for 2018. With the UK National Health Service payment approval today. This is set to be a billion dollar company. Do your DD and dive into Biel $$$$

BioElectronics ActiPatch Drug Free Pain Therapy Receives United Kingdom National Health System Payment Coverage https://finance.yahoo.com/news/bioelectronics-actipatch-drug-free-pain-120000840.htmlg

[9754LB851]

thin L2 w/no dilution.HCEI sos active 12/28, Float 184 mil 1/2/18

CEO posting FB about bitcoin. Volume watch-list

[ClayTrader]

* * $GBLX Video Chart 01-04-18 * *

Link to Video - click here to watch the technical chart video

[Value_Investor]

AFTC: Up 50% from the New Bottom 0.0002! Strong Upward trend --- see the third link below! On Big fire since 06/13 with Huge Slapping volumes! Near 20M shares Slapped at New 52-week high $0.0005 v.s. the Positive Book Value is $0.0007 a share! Meager 61.871M shares FIXED Tiny float and only 592M shares FIXED Small OS from the TA on 11/12! Easy to surge back to its recent high 0.0046 again v.s. at Mere 0.0002 now! Reinstated recently --- see the first link below! Key DME Technologies and Patents etc. IP assets --- see the second link below!

The company ever raised $1,512,000 Huge Cash ($0.0026 a share Cash Value) by offering 18M shares at $0.084 a share v.s. trading at Mere $0.0003 New bottom price now!

To match the Same Market Value with its peers EFLN, NNSR, BRTE, and EVRN, AFTC will hit a New 52-week high 0.0287, 0.0078, 0.0076, and 0.0044 respectively!

http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=0cXzMC3LkbsYtfvFUfEmww%253d%253d&CorpName=ALTERNATIVE+fuel+TECHNOLOGIES%2c+INC.

https://www.aboutdme.org/index.asp?sid=48

http://www.stockta.com/cgi-bin/analysis.pl?symb=AFTC&num1=1&cobrand=&mode=stock

[9754LB851]

INTK thin L2 w/no dilution. industrial technology w/patent

[ClayTrader]

* * $ACBFF Video Chart 01-04-18 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $HTGM Video Chart 01-04-18 * *

Link to Video - click here to watch the technical chart video

[ClayTrader]

* * $SGMD Video Chart 01-04-18 * *

Link to Video - click here to watch the technical chart video